Eisai Company, Limited

Makoto Asada

Kyosuke Kitoh

Hiroyuki Yoshimura

Shigeki Hibi

Norihiro Ueda

Mitsuo Nagai

Tatsuo Watanabe

Yoshihiko Kotake

Jun Niijima

Ieharu Hishinuma

Junichi Nagakawa

Takeshi Nagasu

Takayuki Hida

Nozomu Koyanagi

Hiroshi Yoshino

Kentaro Yoshimatsu

Kappei Tsukahara

Norimasa Miyamoto

Toshimi Okada

Aichi Ogasawara

Atsumi Iijima

Shinya Abe

Katsuya Tagami

Takashi Yamanaka

Kouichi Kikuchi

Hiroyuki Sugumi

Seiko Higashi

Kenji Tai

Isao Yamatsu

Koichi Kikuchi

Kenji Koga

Kiyoshi Tomioka

Hirovuki Sugumi

Mono- or polyenic carboxylic acid derivatives

To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:

Compounds of the formula and compounds of the formula ##STR1## or their salts have the potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis.

Mono-or polyenic carboxylic acid derivatives

Heterocycle-containing carbonic acid derivatives

Sulfonamide compounds of formula (I) or a pharmacologically acceptable salt thereof: ##STR1## exhibit excellent antitumor activity and low toxicity.

Pyrimidinyl or pyridinyl sulfonamide substituted compounds

Sulfonamide compounds of the formula or pharmacologically acceptable salts thereof: ##STR1## wherein: R.sup.1 is a hydrogen atom, halogen atom, lower alkyl group, lower alkoxy group, hydroxyl group, nitro group, phenoxy group, cyano group, acetyl group, amino group or a protected amino group; R.sup.2 and R.sup.3 may be the same or different from each other and each is a hydrogen atom, halogen atom, lower alkyl group or lower alkoxy group; R.sup.4 and R.sup.7 may be the same or different from each other and each is a hydrogen atom or a lower alkyl group; R.sup.5 and R.sup.6 may be the same or different from each other and each is a hydrogen atom, halogen atom, lower alkoxy group, amino group or amino group substituted with a lower alkyl or a phenyl group; A is .dbd.CH--; B is .dbd.CH--; and E is selected from the group consisting of ##STR2## in which Q is an oxygen atom or a sulfur atom; and R.sup.11 is a hydrogen atom, a lower alkyl group, an amino group which may be substituted with a lower alkyl group, a lower alkoxy group, a 2-thienyl group, a 2-furyl group, phenyl group or a phenyl group having from 1 to 3 substituents, said substituents being the same or different from one another and selected from the group consisting of a halogen atom, lower alkyl group, lower alkoxy group, hydroxyl group, carboxyl group, esterified carboxyl group, amidated carboxyl group, lower alkylthio group and phenoxy group; and (b) a phenyl group or a phenyl group having from 1 to 3 substituents.

Sulfonamide phenyl substituted compounds

Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 may be the same or different from one another and each represent a hydrogen atom, halogen atom or lower alkyl group, A and B may be the same or different from each other and each represent .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptance salts of them, have an excellent antitumo-activity.

Sulfonamide derivatives

Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 may be the same or different from one another and each represent a hydrogen atom, halogen atom or lower alkyl group, A and B may be the same or different from each other and each represent .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptable salts of them, have an excellent antitumor activity.

Pyridine carboxamide compounds which have useful as pharmaceutical

Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 may be the same or different from one another and each represent a hydrogen atom, halogen atom or lower alkyl group, A and B may be the same or different from each other and each represent .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptance salts of them, have an excellent antitumor activity.

Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined in the specification, A and B may be the same or different from each other and each represents .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and may be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptance salts of them.

An azacyclooctadiene compound having the formula (1) or a pharmacologically acceptable salt thereof is novel and useful as an anti-tumor agent. ##STR1## in which R1 is --CH2R, R being hydrogen, --COCH3, --OH, --NH2, --COOH or --OCOCH3, or may form --CH2--X--Y-- together with R2; R2 is hydrogen, an alkyl having 1 to 4 carbon atoms or --COR10, R10 being hydrogen, an alkyl having 1 to 4 carbon atoms, --OR11 or --NHR11, R11 being an alkyl having 1 to 4 carbon atoms, or may form --CH2--X--Y-- together with R1; R3, R4 and R5 each are hydrogen or methyl; R6 and R7 each are hydrogen or may form the direct bond to each other; R8 is hydrogen or may form the direct bond to R7; and R9 is hydrogen, --N3, --NH2, --OCH3 or .dbd.0; X being oxygen or --NZ--, Z being hydrogen, methyl, --COCH3, --CH2COOH, --CO--CH.dbd.CH2, --CO--CH.dbd.CH--CH3, --CH2C6H5, --CH2OH, --CH2OCOCH3 or --CH2--COOC(CH3)3, Y being --SC--, --CO-- or --CH2--.

Azacyclooctadiene compound and pharmaceutical use

Growing community of inventors

Ibaraki, Japan

Makoto Asada